GLAXOSMITHKLINE BIOLOGICALS AND AERAS GLOBAL TB VACCINE FOUNDATION PARTNER TO DEVELOP NEW TB VACCINE

GlaxoSmithKline Biologicals (GSK Biologicals) and the Aeras Global TB Vaccine Foundation (Aeras) today announced a new public-private partnership to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A, which has shown promising results in preclinical studies. In addition, the vaccine has shown a good safety and immunogenicity profile in early-stage clinical trials conducted by GSK Biologicals. TB causes 2 million deaths a year, and is a leading cause of death amongst people with AIDS in the developing world.

Yahoo News (http://biz.yahoo.com/prnews/051020/phth035.html?.v=27)